Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions

Nanomedicine

Volumn 7, Issue 6, 2012, Pages 877-888

  Plummer, Emily M ^a,b   Thomas, Diane ^a   Destito, Giuseppe ^b,c   Shriver, Leah P ^a   Manchester, Marianne ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

aorta; atherosclerosis; cowpea mosaic virus; foam cell; imaging; lesion; macrophage; surface vimentin; targeting; viral nanoparticle

Indexed keywords

ALEXA FLUOR 555; COWPEA MOSAIC VIRUS NANOPARTICLE; FLUORESCENT DYE; NANOPARTICLE; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COWPEA; COWPEA MOSAIC VIRUS; ENDOTHELIUM; ENDOTHELIUM CELL; FOAM CELL; INFLAMMATORY CELL; MACROPHAGE; MALE; MOSAIC VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CELL LINE; CELLS, CULTURED; COMOVIRUS; ENDOTHELIAL CELLS; FOAM CELLS; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC; VIMENTIN;

EID: 84862901468     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.185     Document Type: Article

References (66)

1. Slevin M, Badimon L, Grau-Olivares M et al. Combining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis. Mol. Biosyst. 6(3), 444-450 (2010).
2. Cybulsky MI, Jongstra-Bilen J. Resident intimal dendritic cells and the initiation of atherosclerosis. Curr. Opin. Lipidol. 21(5), 397-403 (2010).
3. Tavora F, Cresswell N, Li L, Ripple M, Burke A. Immunolocalisation of fibrin in coronary atherosclerosis: implications for necrotic core development. Pathology 42(1), 15-22 (2010).
4. Ota H, Yu W, Underhill HR et al. Hemorrhage and large lipid-rich necrotic cores are independently associated with thin or ruptured fibrous caps: an in vivo 3T MRI study. Arterioscler. Thromb. Vasc. Biol. 29(10), 1696-1701 (2009).
5. Ovchinnikova O, Gylfe A, Bailey L et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler. Thromb. Vasc. Biol. 29(10), 1478-1480 (2009).
6. Van Den Diepstraten C, Papay K, Bolender Z, Brown A, Pickering JG. Cloning of a novel prolyl 4-hydroxylase subunit expressed in the fibrous cap of human atherosclerotic plaque. Circulation 108(5), 508-511 (2003).
7. Heeneman S, Cleutjens JP, Faber BC et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J. Pathol. 200(4), 516-525 (2003).
8. McNeill E, Channon KM, Greaves DR. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin. Sci. (Lond.) 118(11), 641-655 (2010).
9. Yla-Herttuala S, Bentzon JF, Daemen M et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb. Haemost. 106(1), 1-19 (2011).
10. Ambrose JA. In search of the 'vulnerable plaque': can it be localized and will focal regional therapy ever be an option for cardiac prevention? J. Am. Coll. Cardiol. 51(16), 1539-1542 (2008).
11. Kubo T, Imanishi T, Takarada S et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll. Cardiol. 50(10), 933-939 (2007).
12. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J. Am. Coll. Cardiol. 49(21), 2093-2101 (2007).
13. Carlier SG, De Korte CL, Brusseau E, Schaar JA, Serruys PW, Van Der Steen AF. Imaging of atherosclerosis. Elastography. J. Cardiovasc. Risk 9(5), 237-245 (2002).
14. Madjid M, Naghavi M, Malik BA, Litovsky S, Willerson JT, Casscells W. Thermal detection of vulnerable plaque. Am. J. Cardiol. 90(10C), 36L-39L (2002).
15. Demos SM, Alkan-Onyuksel H, Kane BJ et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J. Am. Coll. Cardiol. 33(3), 867-875 (1999).
16. Unno N, Mitsuoka H, Takei Y et al. Virtual angioscopy using 3-dimensional rotational digital subtraction angiography for endovascular assessment. J. Endovasc. Ther. 9(4), 529-534 (2002).
17. Laitinen I, Saraste A, Weidl E et al. Evaluation of avb3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ. Cardiovasc. Imaging 2(4), 331-338 (2009).
18. Tawakol A, Castano AP, Gad F et al. Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor. Photochem. Photobiol. Sci. 7(1), 33-39 (2008).
19. Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev. Cardiovasc. Ther. 8(11), 1619-1635 (2010).
20. Quillard T, Croce K, Jaffer FA, Weissleder R, Libby P. Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thromb. Haemost. 105(5), 828-836 (2010).
21. Winter PM, Morawski AM, Caruthers SD et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with a(v) b3-integrin-targeted nanoparticles. Circulation 108(18), 2270-2274 (2003).
22. Kuroda S, Mukohyama H, Kondo H et al. Bone mineral density of the mandible in ovariectomized rats: analyses using dual energy X-ray absorptiometry and peripheral quantitative computed tomography. Oral Dis. 9(1), 24-28 (2003).
23. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr. Drug Discov. Technol. 6(1), 43-51 (2009).
24. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler. Thromb. Vasc. Biol. 29(7), 992-1000 (2009).
25. Allen M, Bulte JW, Liepold L et al. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn. Reson. Med. 54(4), 807-812 (2005).
26. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv. Drug Deliv. Rev. 62(3), 329-338 (2010).
27. Lewis JD, Destito G, Zijlstra A et al. Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 12(3), 354-360 (2006).
28. Leong HS, Steinmetz NF, Ablack A et al. Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat. Protoc. 5(8), 1406-1417 (2010).
29. Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog. 5(5), e1000417 (2009).
30. Koudelka KJ, Rae CS, Gonzalez MJ, Manchester M. Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus. J. Virol. 81(4), 1632-1640 (2007).
31. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 5(1), 59-63 (2003).
32. Gonzalez MJ, Plummer EM, Rae CS, Manchester M. Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo. PLoS ONE 4(11), e7981 (2009).
33. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7(2), 77-86 (2010).
34. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann. Med. 42(6), 394-403 (2010).
35. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin. Immunol. 134(1), 5-24 (2010).
36. Webb NR, Moore KJ. Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr. Drug Targets 8(12), 1249-1263 (2007).
37. Siegel-Axel D, Daub K, Seizer P, Lindemann S, Gawaz M. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc. Res. 78(1), 8-17 (2008).
38. Zaragoza C, Gomez-Guerrero C, Martin- Ventura JL et al. Animal models of cardiovascular diseases. J. Biomed. Biotechnol. 2011, 497841 (2011).
39. Merkel M, Velez-Carrasco W, Hudgins LC, Breslow JL. Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice. Proc. Natl Acad. Sci. USA 98(23), 13294-13299 (2001).
40. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J. Biol. Chem. 275(34), 26293-26299 (2000).
41. Jiang Z, Georgel P, Du X et al. CD14 is required for MyD88-independent LPS signaling. Nat. Immunol. 6(6), 565-570 (2005).
42. Rae CS, Khor IW, Wang Q et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343(2), 224-235 (2005).
43. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl. 1), III27-III32 (2004).
44. Eefting FD, Pasterkamp G, Clarijs RJ, Van Leeuwen TG, Borst C. Remodeling of the atherosclerotic arterial wall: a determinant of luminal narrowing in human coronary arteries. Coron. Artery Dis. 8(7), 415-421 (1997).
45. Steinmetz NF, Cho CF, Ablack A, Lewis JD, Manchester M. Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine (Lond). 6(2), 351-364 (2011).
46. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379-387 (2008).
47. Tearney GJ, Yabushita H, Houser SL et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 107(1), 113-119 (2003).
48. Zhang Z, Machac J, Helft G et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl. Med. 6, 3 (2006).
49. Lipinski MJ, Frias JC, Amirbekian V et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc. Imaging 2(5), 637-647 (2009).
50. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J. Infect. Dis. 193(12), 1685-1692 (2006).
51. Garg A, Barnes PF, Porgador A et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J. Immunol. 177(9), 6192-6198 (2006).
52. Huet D, Bagot M, Loyaux D et al. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J. Immunol. 176(1), 652-659 (2006).
53. Leong HS, Mahesh BM, Day JR et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J. Leukoc. Biol. 83(2), 263-271 (2008).
54. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J. Leukoc. Biol. 79(3), 489-498 (2006).
55. Nieminen M, Henttinen T, Merinen M, Marttila-Ichihara F, Eriksson Je, Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell. Biol. 8(2), 156-162 (2006).
56. Podor TJ, Singh D, Chindemi P et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J. Biol. Chem. 277(9), 7529-7539 (2002).
57. Van Beijnum JR, Dings RP, Van Der Linden E et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108(7), 2339-2348 (2006).
58. Xu B, Dewaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, Kahn ML. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol. Cell. Biol. 24(20), 9198-9206 (2004).
59. Levin N, Bischoff ED, Daige CL et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25(1), 135-142 (2005).
60. Liu C, Bhattacharjee G, Boisvert W, Dilley R, Edgington T. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am. J. Pathol. 163(5), 1859-1871 (2003).
61. Lomonossoff GP, Shanks M. The nucleotide sequence of cowpea mosaic virus B RNA. EMBO J. 2(12), 2253-2258 (1983).
62. Chacko AM, Hood ED, Zern BJ, Muzykantov VR. Targeted nanocarriers for imaging and therapy of vascular inflammation. Curr. Opin. Colloid Interface Sci. 16(3), 215-227 (2011).
63. Lewis DR, Kamisoglu K, York AW, Moghe PV. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(4), 400-420 (2011).
64. Douma K, Megens RT, Van Zandvoort MA. Optical molecular imaging of atherosclerosis using nanoparticles: shedding new light on the darkness. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(4), 376-388 (2011).
65. Terashima M, Uchida M, Kosuge H et al. Human ferritin cages for imaging vascular macrophages. Biomaterials 32(5), 1430-1437 (2011).
66. Uchida M, Kosuge H, Terashima M et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5(4), 2493-2502 (2011).